Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Medidata Solutions (MDSO) Stock Price

News stories about Medidata Solutions (NASDAQ:MDSO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medidata Solutions earned a news impact score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.748485478419 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Medidata Solutions (NASDAQ MDSO) opened at $66.11 on Thursday. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $3,911.04, a price-to-earnings ratio of 94.44, a price-to-earnings-growth ratio of 3.47 and a beta of 1.69. Medidata Solutions has a 1 year low of $47.77 and a 1 year high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. The business had revenue of $140.08 million during the quarter, compared to analyst estimates of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. Medidata Solutions’s revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS. equities research analysts predict that Medidata Solutions will post 0.78 earnings per share for the current year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. SunTrust Banks restated a “buy” rating and set a $92.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. Wells Fargo & Co dropped their price objective on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a report on Friday, October 27th. Dougherty & Co assumed coverage on Medidata Solutions in a report on Thursday, November 2nd. They set a “neutral” rating for the company. Finally, Royal Bank of Canada restated a “hold” rating and set a $80.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $84.54.

In other Medidata Solutions news, EVP Michael I. Otner sold 10,000 shares of Medidata Solutions stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total transaction of $708,800.00. Following the completion of the sale, the executive vice president now directly owns 80,674 shares of the company’s stock, valued at approximately $5,718,173.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Pray sold 5,944 shares of Medidata Solutions stock in a transaction on Friday, November 17th. The shares were sold at an average price of $70.47, for a total value of $418,873.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 239,010 shares of company stock valued at $16,437,036. 5.80% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was originally published by Week Herald and is the property of of Week Herald. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://weekherald.com/2018/01/18/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-medidata-solutions-mdso-stock-price.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply